BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T122956
CREATED:20181206T115237Z
LAST-MODIFIED:20200320T123611Z
UID:18694-1603670400-1603843199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes East Coast 2020
DESCRIPTION:SMi are proud to announce the 7th annual conference: \nPre-Filled Syringes East Coast 2020\n26-27 October 2020\nBoston\, USA\nSheraton Boston Hotel\nhttp://www.pfsamericas.com/pjwl \nInnovations in parenteral device and product development \n \nSMi Group are proud to announce the 7th Pre-Filled Syringes East Coast conference returning to Boston\, USA on 26th-27th October 2020. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, for its 7th year running- the 2020 event will aim to focus on new trends on digital technology advancements\, human studies and innovative design and delivery systems within the prefilled syringe industry. \nThemes for 2020: \nPre-Filled Syringes East Coast 2020 will be exploring themes of Container Closure Interaction and Formulation; On-body Injectors; Digital connectivity in the parenteral space; A regulatory outlook with industry and recognised body experts; Patient centricity and device development; Developments in device technology; Parenteral gene therapy and New for 2020: PFS Interactive Workshop Day. \nThis comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more.. \nKey Reasons to Attend: \n\nEXPLORE the latest case studies parenteral drug delivery\nGAIN insights into the use of pre-filled syringes for gene therapy\nNETWORK with leading industry experts\, key opinion leaders and regulatory body representatives\nENGAGE in the key challenges and topics of the field in the interactive post-conference workshop day\n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nTo register or for more information visit: www.pfsamericas.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/prefilled-syringes-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SMi Group Ltd":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201029
DTSTAMP:20260515T122956
CREATED:20191215T134154Z
LAST-MODIFIED:20200813T143407Z
UID:23372-1603670400-1603929599@www.pharmajournalist.com
SUMMARY:Smithers’ Extractables and Leachables USA 2020
DESCRIPTION:Smithers’ 9th annual Extractables and Leachables USA conference is returning. This is a unique event in the extractables and leachables industry\, bringing together top companies from the entire supply chain and making it easy to network with peers\, leading to new\, beneficial connections. The event is a must for the extractables and leachables industry\, wherein players need to stay on top of market changes\, fluctuating regulations\, medical device strategies\, and safety standards for consumer safety and product success. Smithers’ E&L 2020 gathers industry experts to discuss these topics\, and more. The program consists of two days of industry-leading presentations by over 20 expert speakers\, supplemented by valuable networking breaks\, an included networking lunch\, and a networking reception at the end of day one. \nCompanies who have attended in the past include B Braun\, The FDA\, Toxikon\, Intertek\, Abbott\, Nelson Laboratories\, Boston Scientific\, Vimta\, Jordi Labs\, VR Analytical\, Teknor Apex\, and many more. \nVisit the event website for more information: https://www.eandl-conference.com/usa. \nContact Producer Ashli Speed\, ASpeed@Smithers.com\, with questions about the program. \nFor companies interested in increasing their brand visibility in front of a target market\, contact Shannon Siegferth\, SSiegferth@Smithers.com\, about sponsorship opportunities. \nTo get the latest updates\, follow the event on twitter @SmithersELEvent\, join the LinkedIn group Extractables and Leachables Forum\, or join the mailing list: https://www.eandl-conference.com/usa/register-interest.
URL:https://www.pharmajournalist.com/event/extractables-and-leachables-usa/
LOCATION:Virtual Event
ORGANIZER;CN="Smithers":MAILTO:sheitzenrater@smithers.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T122956
CREATED:20200806T100433Z
LAST-MODIFIED:20200806T100433Z
UID:26627-1603670400-1603843199@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Summit
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research in a dedicated\, two day meeting. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings for your future research. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a meeting that brings together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, this event will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Summit website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201029
DTSTAMP:20260515T122956
CREATED:20200817T085404Z
LAST-MODIFIED:20200817T085404Z
UID:26772-1603670400-1603929599@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders Europe | Running Digitally for 2020
DESCRIPTION:Realise the Commercial Potential of Gene Therapies \nThe 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming\nmanufacturing\, clinical\, and commercialisation challenges drug developers face when delivering\ngene therapies to market. \nWith new European gene therapy approvals rapidly approaching and investment at an all-time high\, the digital meeting will leverage the experience from the first to market pioneers\, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy\, safety and commercial viability. \n \nAcross three days\, we will virtually unite 250+ leading experts from innovative biotechs\, large pharmaceutical companies\, academia\, and key service providers. Understand the nuances of the European regulatory landscape\, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come. \nWherever you’re based\, if you’re looking to develop and launch gene therapy products in Europe\, this is your comprehensive guide to define your commercial path forward \nTo learn more about Gene Therapy for Rare Disorders Europe please click here: https://ter.li/k19u77
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders-europe-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T122956
CREATED:20200716T134602Z
LAST-MODIFIED:20200716T135026Z
UID:26349-1603756800-1603843199@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-2/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T122956
CREATED:20200722T112338Z
LAST-MODIFIED:20200722T112338Z
UID:26438-1603756800-1604015999@www.pharmajournalist.com
SUMMARY:Macrophage-directed Therapies Summit 2020
DESCRIPTION:Harnessing the Potential of Macrophage Therapies Using Small Molecule\, Antibody & Cell Therapy based Approaches for Oncology and Beyond \nWith the explosive excitement and clinical proof of concepts utilizing CD47 approaches\, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47. \n \nThe 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies\, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond. \nBringing together the leading experts\, we will explore the clinical development of CD47 checkpoint blockades\, combination strategies\, macrophage repolarization approaches and engineered macrophages. \nJoin the trailblazers of macrophage therapeutic development\, from the likes of Carisma Therapeutics\, Faron Pharmaceuticals\, and Verseau Therapeutic\, as we come together to advance the fundamental understanding of macrophage biology\, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.
URL:https://www.pharmajournalist.com/event/macrophage-directed-therapies-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR